Journals | Policy | Permission

World Journal of Oncology

Editorial

Volume 14, Number 1, February 2023, pages 1-3

Biomarker Research in World Journal of Oncology

In this issue of World Journal of Oncology, Desai et al review carcinoembryonic antigen (CEA), carbohydrate antigen-19-9 (CA19-9), CA125, prostate surface antigen (PSA) and other cancer biomarkers [1], and Chen et al report vascular endothelial growth factor-C (VEGF-C) as a lung adenocarcinoma prognostic biomarker [2]. Biomarker research has gained such popularity during the last 30 years that the publication count on the topic increases exponentially every year. There were more than 74,000 publications in 2022 alone, and more than 1,100,000 manuscripts total with the keyword “biomarker” searchable in the PubMed database (searched February 2023). According to the United States National Cancer Institute, “biomarker” is defined as “A biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition.” As such, cancer biomarkers can be functionally classified into diagnostic (screening) biomarkers, prognostic biomarkers, and predictive biomarkers, where the latter two are the ones that most people presume when the word “biomarker” is used in the context of cancer management. It is important to note that prognostic biomarkers are associated with cancer outcomes, while predictive biomarkers discriminate response to therapy. For instance, cancer staging defined by the American Joint Committee on Cancer (AJCC) is a prognostic biomarker, such that patients with stage IV cancer have worse survival compared to the other stages. Chen et al claim that VEGF-C is a prognostic biomarker because they found that when its gene expression was low, it was associated with better overall survival in lung adenocarcinoma. One example of a predictive biomarker is programmed death-ligand 1 (PD-L1) expression because anti-PD1 immunotherapy targets that mechanism, although it is reported that some patients respond to the therapy even without detectable PD-L1 expression for unknown reasons. Purwanto et al reported in World Journal of Oncology that PD-L1 gene expression was associated with worse overall survival in Indonesian triple-negative breast cancer patients who did not receive anti-PD1 immunotherapy, and thus PD-L1 was evaluated as a prognostic biomarker in this case [3]. This finding was not replicated in Mexican women [4].

The expressions of breast cancer biomarkers such as the estrogen receptor and the human epidermal growth factor 2 (HER2) receptor determine whether the target therapies (hormonal therapy and anti-HER2 targeted therapy, respectively) are applicable, and therefore they are predictive biomarkers. Indeed, the distribution of these biomarkers in Nigerian women was reported by Adeniji et al [5], in Jamaican women by Copeland et al [6], and in Mexican women by Macari et al [7] in World Journal of Oncology. Estrogen receptor status is a critical predictive biomarker not only for hormonal therapies that directly interact with the receptor or its signaling, but for other targeted therapies such as cyclin-dependent kinase (CDK) 4 and 6 inhibitors that also have therapeutic effects only in this population [8, 9].

Given the powerful predictive biomarkers of estrogen, progesterone, and HER2 receptors expressions, it is typical for breast cancer to be divided into subtypes that correspond to receptor expression status: 70% are luminal (estrogen receptor-positive), 10-15% are HER2-overexpressing, and 10-20% are triple-negative. This typical classification scheme is changing with a recognition of a new predictive biomarker, “HER2-low”. Traditional HER2-targeted therapy using trastuzumab or pertuzumab was indicated only for HER2-overexpressed breast cancers determined as 3+ staining by immunohistochemistry or 2+ staining by immunohistochemistry and positive by fluorescent in situ hybridization (FISH). However, Modi et al recently reported in the New England Journal of Medicine (July 2022) that HER2-low tumors, currently defined as HER2 1+ or 2+ by immunohistochemistry with negative FISH, are treatable using trastuzumab deruxtecan, a HER2 targeting antibody-topoisomerase 1 inhibitor conjugate [10]. Apparently, approximately 50-60% of non-HER2 overexpressing and 35% of triple-negative breast cancers are HER2-low [11, 12]. To this end, the predictive biomarker distribution in breast cancer is now 50% HER2-low, 25% luminal, 15% HER2 overexpressing, and 10% triple-negative [13].

As such, the discovery of predictive biomarkers can change how we recognize a cancer, and this is most likely one of the reasons for the recent explosion of publications on this topic. Therefore, we predict that the race to identify powerful predictive biomarkers will continue. Ultimately, prognostic biomarkers that identify patients with poor survival odds but do not provide treatment information are less useful than predictive biomarkers. To this end, our group has also been aggressively pursuing this line of research not only to identify single gene expression biomarkers (maternal embryonic leucine zipper kinase (MELK) [14], inositol-trisphosphate 3-kinase (ITPKC) [15], androgen receptor [16]), but also scores combining multiple gene expressions (5-gene score [17], 4-gene score [18], 3-gene score [19]), cell infiltrations (regulatory T cells [20], T-helper 2 (Th2) cells [21]) and activation of signaling pathways (E2F targets [22], G2M checkpoint [23]). We expect to receive more manuscript submissions to the World Journal of Oncology on this end in the near future.

Acknowledgments

This research was supported by grants from the United States National Institutes of Health (R37CA248018, R01CA250412, R01CA251545, and R01EB029596) and the US Department of Defense (BCRP W81XWH-19-1-0674 and W81XWH-19-1-0111) to K.T. The National Cancer Institute Cancer Center Support Grant P30CA016056 supports Roswell Park Comprehensive Cancer Center.

Financial Disclosure

None to declare.

Conflict of Interest

None to declare.

Author Contributions

Conceptualization and design of study: KT. Editing of the paper: KT and MGKB.

Data Availability

The authors declare that data supporting the findings of this study are available within the article.

1. Desai S, Guddati AK. Carcinoembryonic antigen, carbohydrate antigen 19-9, cancer antigen 125, prostate-specific antigen and other cancer markers: a primer on commonly used cancer markers. World J Oncol. 2023;14(1):4-14.
   doi
2. Chen S, Pan TY, Wu X, Li T, Wei Y, He HL, Zhou XM,, et al. Uses of vascular endothelial growth factor C as a lung adenocarcinoma prognostic biomarker. World J Oncol. 2023;14(1):51-59.
   doi
3. Purwanto I, Heriyanto DS, Ghozali A, Widodo I, Dwiprahasto I, Aryandono T, Haryana SM. Overexpression of programmed death-ligand 1 receptor mRNA as an independent negative prognostic factor for triple negative breast cancer. World J Oncol. 2020;11(5):216-222.
   doi pubmed
4. Erraez-Jaramillo PJ, Aguirre-Flores E, Athie-Meza LF, Morales-Garcia MG, Izquierdo-Tolosa CD, Martinez-Castaneda EA, Ruiz-Morales JM, et al. Expression of programmed death ligand 1 in breast cancer in mexican women. World J Oncol. 2022;13(4):185-189.
   doi pubmed
5. Adeniji AA, Dawodu OO, Habeebu MY, Oyekan AO, Bashir MA, Martin MG, Keshinro SO, et al. Distribution of breast cancer subtypes among Nigerian women and correlation to the risk factors and clinicopathological characteristics. World J Oncol. 2020;11(4):165-172.
   doi pubmed
6. Copeland J, Oyedeji A, Powell N, Cherian CJ, Tokumaru Y, Murthy V, Takabe K, et al. Breast cancer in Jamaica: stage, grade and molecular subtype distributions across age blocks, the implications for screening and treatment. World J Oncol. 2021;12(4):93-103.
   doi pubmed
7. Macari A, Soberanis-Pina P, Varela-Santoyo E, Valle-Sanchez MA, Leal-Hidalgo JL, Torres-Guillen VM, Motola-Kuba D, et al. Prevalence and molecular profile of breast carcinoma using immunohistochemistry markers in Mexican women. World J Oncol. 2021;12(4):119-123.
   doi pubmed
8. Miyahara K, Narui K, Uemura Y, Yamada A, Araki K, Fujisawa F, Nakayama T, et al. Prospective cohort study of combination therapy with Abemaciclib and hormonal therapy for chemotherapy-treated patients with hormone receptor-positive metastatic breast cancer. World J Oncol. 2022;13(4):216-221.
   doi pubmed
9. Narui K, Ishikawa T, Taira N, Uemura Y, Mukai H. Prospective cohort study of Palbociclib treatment in postmenopausal patients with unresectable and metastatic hormone receptor-positive breast cancer: study protocol for a CSPOR-BC palbociclib cohort trial. World J Oncol. 2022;13(4):190-194.
   doi pubmed
10. Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9-20.
    doi pubmed
11. Gampenrieder SP, Rinnerthaler G, Tinchon C, Petzer A, Balic M, Heibl S, Schmitt C, et al. Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry. Breast Cancer Res. 2021;23(1):112.
    doi pubmed
12. Schettini F, Chic N, Braso-Maristany F, Pare L, Pascual T, Conte B, Martinez-Saez O, et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ Breast Cancer. 2021;7(1):1.
    doi pubmed
13. Tarantino P, Hamilton E, Tolaney SM, Cortes J, Morganti S, Ferraro E, Marra A, et al. HER2-low breast cancer: pathological and clinical landscape. J Clin Oncol. 2020;38(17):1951-1962.
    doi pubmed
14. Oshi M, Gandhi S, Huyser MR, Tokumaru Y, Yan L, Yamada A, Matsuyama R, et al. MELK expression in breast cancer is associated with infiltration of immune cell and pathological compete response (pCR) after neoadjuvant chemotherapy. Am J Cancer Res. 2021;11(9):4421-4437.
15. Oshi M, Newman S, Murthy V, Tokumaru Y, Yan L, Matsuyama R, Endo I, et al. ITPKC as a prognostic and predictive biomarker of neoadjuvant chemotherapy for triple negative breast cancer. Cancers (Basel). 2020;12(10):2758.
    doi pubmed
16. Okano M, Oshi M, Butash AL, Asaoka M, Katsuta E, Peng X, Qi Q, et al. Estrogen receptor positive breast cancer with high expression of androgen receptor has less cytolytic activity and worse response to neoadjuvant chemotherapy but better survival. Int J Mol Sci. 2019;20(11):2655.
    doi pubmed
17. Oshi M, Gandhi S, Angarita FA, Kim TH, Tokumaru Y, Yan L, Matsuyama R, et al. A novel five-gene score to predict complete pathological response to neoadjuvant chemotherapy in ER-positive/HER2-negative breast cancer. Am J Cancer Res. 2021;11(7):3611-3627.
18. Oshi M, Katsuta E, Yan L, Ebos JML, Rashid OM, Matsuyama R, Endo I, et al. A novel 4-gene score to predict survival, distant metastasis and response to neoadjuvant therapy in breast cancer. Cancers (Basel). 2020;12(5):1148.
    doi pubmed
19. Oshi M, Angarita FA, Tokumaru Y, Yan L, Matsuyama R, Endo I, Takabe K. A novel three-gene score as a predictive biomarker for pathologically complete response after neoadjuvant chemotherapy in triple-negative breast cancer. Cancers (Basel). 2021;13(10):2401.
    doi pubmed
20. Oshi M, Asaoka M, Tokumaru Y, Angarita FA, Yan L, Matsuyama R, Zsiros E, et al. Abundance of regulatory T Cell (Treg) as a predictive biomarker for neoadjuvant chemotherapy in triple-negative breast cancer. Cancers (Basel). 2020;12(10):3038.
    doi pubmed
21. Le L, Tokumaru Y, Oshi M, Asaoka M, Yan L, Endo I, Ishikawa T, et al. Th2 cell infiltrations predict neoadjuvant chemotherapy response of estrogen receptor-positive breast cancer. Gland Surg. 2021;10(1):154-165.
    doi pubmed
22. Oshi M, Takahashi H, Tokumaru Y, Yan L, Rashid OM, Nagahashi M, Matsuyama R, et al. The E2F pathway score as a predictive biomarker of response to neoadjuvant therapy in ER+/HER2- breast cancer. Cells. 2020;9(7):1643.
    doi pubmed
23. Oshi M, Takahashi H, Tokumaru Y, Yan L, Rashid OM, Matsuyama R, Endo I, et al. G2M cell cycle pathway score as a prognostic biomarker of metastasis in estrogen receptor (ER)-positive breast cancer. Int J Mol Sci. 2020;21(8):2921.
    doi pubmed

This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

World Journal of Oncology is published by Elmer Press Inc.